USPTO Examiner RONEY CELESTE A - Art Unit 1612

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
18986700LONG-ACTING LIPOSOMAL COMPOSITION FOR TREATMENT OF PAIN IN ARTICULAR DISORDERSDecember 2024September 2025Allow920YesNo
18912716LIPID NANOPARTICLESOctober 2024July 2025Allow911NoNo
18906740METHOD OF DELIVERY OF DNA OR RNA CARGO USING UNSHIELDED LIPID NANOPARTICLES AND COMPOSITIONS THEREOFOctober 2024March 2025Allow510NoNo
18806627Technology for improving properties of lipid nanoparticles using lipids in which cis-unsaturated bonds are substiuted with a silicon atomAugust 2024March 2025Allow710NoNo
18765624Fenugreek Formulation for Lowering Blood Glucose and Weight LossJuly 2024February 2025Allow711NoNo
18718353SUPRAMOLECULAR HYDROGEL FOR LIPOPHILIC DRUG DELIVERY, A PREPARATION METHOD THEREFOR, AND USE THEREOFJune 2024March 2025Allow910NoNo
18632083TREATMENT OF HEMATOLOGICAL DISORDERSApril 2024February 2026Allow2220NoNo
18619103Application of AuCs or Substances Containing AuCs in the Preparation of Drugs for Preventing and/or Treating GlaucomaMarch 2024April 2025Allow1210NoNo
18611735NANO LIQUID COMPOSITION CONTAINING CURCUMIN HAVE THE ABILITY TO TREATING BURNS AND INCREASING THE EFFECT OF SCAR HEALING AND METHOD OF MANUFACTURING THE SAMEMarch 2024July 2024Allow410NoNo
18608522OPHTHALMIC FORMULATIONMarch 2024July 2025Abandon1610NoNo
18589567Foaming Oral Care CompositionsFebruary 2024September 2025Allow1820NoNo
184360009-(2-HYDROXYQUINOLINE-3-YL)-10-[3-(DIMETHYLAMINO)PROPYL]-3,4,6,7,9,10-HEXAHYDROACRIDINE-1,8(2H,5H)-DIONE AS AN ANTIMICROBIAL COMPOUNDFebruary 2024May 2024Allow300NoNo
184359999-(2-HYDROXYQUINOLINE-3-YL)-10-[3-(DIMETHYLAMINO)PROPYL]-3,4,6,7,9,10-HEXAHYDROACRIDINE-1,8(2H,5H)-DIONE AS AN ANTIMICROBIAL COMPOUNDFebruary 2024June 2024Allow500NoNo
18391712INHALABLE COMPOSITIONS FOR USE IN THE TREATMENT OF PULMONARY DISEASESDecember 2023December 2024Allow1110NoNo
18533497NANOEMULSION WITHOUT PROPYLENE GLYCOLDecember 2023December 2024Allow1221YesNo
18519251LEAVE-ON ORAL CARE COMPOSITIONSNovember 2023September 2025Allow2221NoNo
183875259-(2-HYDROXYQUINOLINE-3-YL)-10-[3-(DIMETHYLAMINO)PROPYL]-3,4,6,7,9,10-HEXAHYDROACRIDINE-1,8(2H,5H)-DIONE AS AN ANTIMICROBIAL COMPOUNDNovember 2023March 2024Allow411NoNo
18387296IONIZABLE LIPIDS AND COMPOSITIONS FOR NUCLEIC ACID DELIVERYNovember 2023June 2025Allow1910NoNo
18490255BLENDED FORMULATIONSOctober 2023February 2025Abandon1610NoNo
18488942FORMULATION OF EAR DROPS AND METHODS FOR DELIVERY THEREOF FOR TREATING UPPER RESPIRATORY INFECTIONSOctober 2023May 2024Allow721YesNo
18480678Dosing Regimens for Treatment of Proliferative DisordersOctober 2023October 2025Allow2431NoNo
18372979PARENTERAL FORMULATIONS AND USES THEREOFSeptember 2023May 2025Allow2021NoNo
18450414NANO LIQUID COMPOSITION CONTAINING CURCUMIN HAVE THE ABILITY TO TREATING BURNS AND INCREASING THE EFFECT OF SCAR HEALING AND METHOD OF MANUFACTURING THE SAMESeptember 2023August 2024Abandon1221NoNo
18460235IMMEDIATE RELEASE DOSAGE FORMSeptember 2023January 2025Allow1711NoNo
18457090METHOD OF MAKING LIPID-ENCAPSULATED RNA NANOPARTICLESAugust 2023September 2024Allow1310NoNo
18279156DENDRIMER-N-ACETYL-L-CYSTEINE CONJUGATES FOR TREATMENT OR PREVENTION OF AGING SKIN OR OTHER INDICATIONSAugust 2023September 2025Abandon2421NoNo
18546414METHODS AND COMPOSITIONS FOR MODULATING PLASMINOGENAugust 2023November 2025Allow2711NoNo
18359271COMPOSITIONS COMPRISING N-ACETYL METHYL GABA AND RELATED METHODSJuly 2023September 2024Allow1410NoNo
18358062COMPOSITIONS COMPRISING N-ACETYL METHYL GABA AND RELATED METHODSJuly 2023September 2024Allow1410NoNo
18357622COMPOSITIONS COMPRISING N-ACETYL METHYL GABA AND RELATED METHODSJuly 2023September 2024Allow1410NoNo
18225323MICROPARTICLE-BASED ENZYME SYSTEMS FOR SELECTIVE REMOVAL OF TARGET MOLECULESJuly 2023March 2026Abandon3110NoNo
18223205ANTI-MICROBIAL SOLUTION FOR SEEDS, CROPS, LIVESTOCK AND PROCESSED FOODSJuly 2023August 2024Allow1310YesNo
18350926Dry Powder Treprostinil for the Treatment of Pulmonary HypertensionJuly 2023December 2024Allow1710NoNo
18217172Method of Preventing and Treating Chemotherapy-Induced AlopeciaJune 2023November 2024Allow1731NoNo
18343636Atropine Pharmaceutical CompositionsJune 2023March 2024Allow800NoNo
18211428CHEMOEMBOLIZATION AGENTSJune 2023March 2025Allow2111NoNo
18336433TREATMENT METHOD FOR TEETH AND GUMSJune 2023February 2024Allow810NoNo
18333375COMPOSITIONS AND METHODS FOR TREATING VASCULAR ANOMALIES, NEVUS SEBACEOUS SYNDROME, EPIDERMAL NEVI, AND NEUROFIBROMASJune 2023March 2025Allow2120NoNo
18255158CD1D-LIGAND-COMPOUND-CONTAINING LIPOSOME PREPARATION HAVING IMPROVED PHARMACOKINETICSMay 2023December 2025Allow3110NoNo
18201901LNP AND LIPOSOME COMPOSITIONS FOR LONGEVITY IN MAMMALS AND METHODS OF USING THE SAMEMay 2023January 2026Abandon3210NoNo
18315011SILYL LIPIDS SUITABLE FOR ENHANCED DELIVERY OF ANTI-VIRAL THERAPEUTICSMay 2023April 2024Allow1121NoNo
18195330TERMITE REPELLANT AND WOOD PROTECTOR AND METHODSMay 2023September 2024Abandon1601NoNo
18311616COMPOSITIONS AND METHODS FOR TARGETED DELIVERY TO CELLSMay 2023March 2024Allow1121NoNo
18310999CAPSULE FOR TREATING ULCERATIVE COLITISMay 2023April 2025Allow2320NoNo
18142532SYSTEMS FOR TREATING PULMONARY INFECTIONSMay 2023July 2024Abandon1410NoNo
18307718CORTICOTROPIN RELEASING FACTOR RECEPTOR ANTAGONISTSApril 2023February 2024Allow1010YesNo
18138774DEODORANT INCLUDING AT LEAST ONE FRUIT ACID AND METHODS OF USING THE SAMEApril 2023January 2025Allow2121NoNo
18135286PURIFICATION OF CLINOPTILOLITEApril 2023April 2025Allow2421NoNo
18301661Particle Modifiers for Multi-Drug Loaded NanoparticlesApril 2023March 2026Abandon3501NoNo
18300233TREATMENT OF CARTILAGE DEGENERATION USING MYELOID SUPPRESSOR CELLS AND EXOSOMES DERIVED THEREOFApril 2023February 2026Abandon3410NoNo
18130092Oral Care Compositions Comprising FluorideApril 2023September 2025Allow2920NoNo
18185630COMPOSITIONS AND USES THEREOF IN TREATING CANCERSMarch 2023February 2026Allow3520NoNo
18120770LIPOSOMAL FORMULATIONS FOR INHIBITING SARS-CoV-2 REPLICATION AND REDUCING LUNG INFLAMMATIONMarch 2023March 2025Allow2421YesNo
18180656LOW VOLATILITY PROMOTING WATER CONDITIONING ADJUVANTSMarch 2023November 2025Abandon3211NoNo
18024899PHOSPHOLIPIDMarch 2023September 2025Allow3100NoNo
18117049IONIZABLE LIPIDS AND COMPOSITIONS FOR NUCLEIC ACID DELIVERYMarch 2023August 2023Allow501NoNo
18024040METHODS FOR TREATING NEWLY DIAGNOSED MYCOBACTERIUM AVIUM COMPLEX LUNG INFECTIONSFebruary 2023December 2025Abandon3410NoNo
18023360COMPOUND AND MRI CONTRAST AGENT CONTAINING SAMEFebruary 2023August 2025Allow3000NoNo
18173980COMPOSITIONS FOR USE IN THE TREATMENT AND PREVENTION OF CARDIOVASCULAR DISORDERS RESULTING FROM CEREBROVASCULAR INJURYFebruary 2023December 2023Allow1010NoNo
18041891LIPID DELIVERY SYSTEMS FOR DELIVERY OF OXALIPLATIN PALMITATE ACETATEFebruary 2023November 2025Abandon3310NoNo
18040454PHARMACEUTICAL COMPOSITION OF INTRA-ARTICULAR CORTICOSTEROID FOR PAIN CONTROLFebruary 2023October 2025Allow3210NoNo
18164174POLYMER BASED FORMULATION FOR RELEASE OF DRUGS AND BIOACTIVES AT SPECIFIC GIT SITESFebruary 2023April 2024Abandon1401NoNo
18159010Lipid nanoparticles containing silyl lipids for use in vaccines and gene therapyJanuary 2023April 2024Allow1421NoNo
18017377COMPOSITIONS COMPRISING miR-690 AND METHODS THEREFORJanuary 2023February 2026Allow3720NoNo
17754177STING AGONIST COMPRISING EXOSOMES FOR TREATING NEUROIMMUNOLOGICAL DISORDERSJanuary 2023December 2025Allow4510NoNo
18005349A COMPOSITE FERRITE NANOPARTICLE WITH SYNERGISTIC ENHANCEMENT OF LIVER SPECIFICITY AND PREPARATION METHOD AND APPLICATION THEREOFJanuary 2023February 2026Allow3710NoNo
18078649CORTICOTROPIN RELEASING FACTOR RECEPTOR ANTAGONISTSDecember 2022July 2025Allow3240NoNo
18009604COMPOSITIONS AND METHODS FOR TREATING DISEASES AND DISORDERS USING FOURNIERELLA MASSILIENSISDecember 2022November 2025Abandon3610NoNo
18063227COMPOSITIONS AND METHODS FOR TREATING PAIN WITH EXTRACELLULAR VESICLESDecember 2022September 2024Allow2110NoNo
17928058Dynamically crosslinked injectable hydrogels with chemically stabilized multilamellar vesiclesNovember 2022February 2026Abandon3910NoNo
17999038HONEYBEE REPELLENTNovember 2022December 2025Abandon3710NoNo
17925262Myelin Nanovesicles And Uses ThereofNovember 2022March 2026Allow4011NoNo
18049264PHARMACEUTICAL PREPARATION WITH TRACING FUNCTION AND DELIVERY SYSTEM THEREFOROctober 2022March 2026Abandon4011NoNo
18046719PHARMACEUTICAL COMPOSITION COMPRISING STEM CELL-CONDITIONED MEDIUM AND EXOSOME ISOLATED THEREFROM AS ACTIVE INGREDIENT FOR PREVENTION OR TREATMENT OF OCULAR DISEASEOctober 2022January 2024Allow1520NoNo
17965880NANOPARTICLE FOR THE REMODELING OF CANCER-ASSOCIATED FIBROBLASTSOctober 2022March 2025Allow2911NoNo
17960076INJECTABLE COMPOSITIONS OF TRITERPENOID ANTIFUNGALS ENCAPSULATED IN LIPOSOMESOctober 2022May 2024Abandon2010YesNo
17916091METAL NUCLIDE-LOADED CARBON MICROSPHERE (CMS), PREPARATION METHOD, AND USE THEREOFSeptember 2022November 2025Allow3820YesNo
17914842ARECOLINE SALT AND PREPARATION METHOD AND PRODUCT THEREOFSeptember 2022November 2025Allow3720YesNo
17952300ORAL FILM FORMULATION FOR MODULATING ABSORPTION PROFILESeptember 2022March 2024Allow1810NoNo
17934873BORTEZOMIB COMPOSITIONSSeptember 2022December 2023Abandon1521NoNo
17948184MODULATION OF THE NITRIC OXIDE SYNTHASE PATHWAY FOR ORAL HEALTHSeptember 2022November 2023Allow1410NoNo
17912312CAR Peptide for Improved Coronavirus SurvivalSeptember 2022December 2025Allow3911NoNo
17930872METHODS OF GENERATING CROSS-LINKED PROTEIN FOAMS IN SITUSeptember 2022December 2024Allow2711NoNo
17903989TERMITE REPELLENT AND WOOD PROTECTORSeptember 2022October 2023Allow1401NoNo
17903974TERMITE REPELLANT AND WOOD PROTECTORSeptember 2022October 2023Allow1301NoNo
17899194EVALUATING DRUG EFFICACY BY USING WEARABLE SENSORSAugust 2022December 2025Allow3910YesNo
17892496LAYER-BY-LAYER NANOPARTICLES FOR CYTOKINE THERAPY IN CANCER TREATMENTAugust 2022December 2023Allow1610NoNo
17874890CANNABINOID COMPOSITIONS AND METHODS OF USING FOR THE TREATMENT OF NON-EOSINOPHILIC INFLAMMATION AND INFLAMMATORY DISORDERSJuly 2022September 2023Abandon1321NoNo
17868323DELAYED RELEASE PHARMACEUTICAL FORMULATIONS COMPRISING VALPROIC ACID, AND USES THEREOFJuly 2022February 2024Allow1920NoNo
17867235MICROPARTICLE FORMULATIONS OF ADENOSINE RECEPTOR ANTAGONISTS FOR TREATING CANCERJuly 2022October 2024Abandon2711NoNo
17865426INHALABLE COMPOSITIONS FOR USE IN THE TREATMENT OF PULMONARY DISEASESJuly 2022November 2023Allow1610YesNo
17862635NAIL COATING SYSTEMJuly 2022March 2024Abandon2001NoNo
17809554Application of AuCs or Substances Containing AuCs in the Preparation of Drugs for Preventing and/or Treating GlaucomaJune 2022February 2024Allow2011NoNo
17786448PIGMENT SUSPENSION AND COSMETIC AGENT PREPARED BY USING THE PIGMENT SUSPENSIONJune 2022July 2025Abandon3701NoNo
17841975COMPOSITIONS AND METHODS FOR USING ALTERNATING ELECTRIC FIELDS TO DISRUPT LIPID CAPSULESJune 2022March 2026Allow4510NoNo
17832208HIGH LIQUIDUS VISCOSITY BIOACTIVE GLASSJune 2022January 2024Allow1911NoNo
17831459PHARMACEUTICAL COMPOSITION AND USES THEREOFJune 2022March 2026Abandon4531NoNo
17735969Compositions and Methods for the Removal of TattoosMay 2022October 2024Allow3010NoNo
17770482WATER-IN-OIL EMULSION SUNSCREEN COSMETICApril 2022March 2026Allow4730NoNo
17724554Pharmaceutical Composition Comprising an Artemisinin Derivative for Nasal or Pulmonary DeliveryApril 2022August 2024Abandon2820NoNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner RONEY, CELESTE A.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
22
Examiner Affirmed
18
(81.8%)
Examiner Reversed
4
(18.2%)
Reversal Percentile
29.7%
Lower than average

What This Means

With a 18.2% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.

Strategic Value of Filing an Appeal

Total Appeal Filings
88
Allowed After Appeal Filing
23
(26.1%)
Not Allowed After Appeal Filing
65
(73.9%)
Filing Benefit Percentile
37.8%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 26.1% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is below the USPTO average, suggesting that filing an appeal has limited effectiveness in prompting favorable reconsideration.

Strategic Recommendations

Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.

Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Examiner RONEY, CELESTE A - Prosecution Strategy Guide

Executive Summary

Examiner RONEY, CELESTE A works in Art Unit 1612 and has examined 661 patent applications in our dataset. With an allowance rate of 59.6%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 31 months.

Allowance Patterns

Examiner RONEY, CELESTE A's allowance rate of 59.6% places them in the 20% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.

Office Action Patterns

On average, applications examined by RONEY, CELESTE A receive 2.73 office actions before reaching final disposition. This places the examiner in the 80% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by RONEY, CELESTE A is 31 months. This places the examiner in the 53% percentile for prosecution speed. Prosecution timelines are slightly faster than average with this examiner.

Interview Effectiveness

Conducting an examiner interview provides a +23.9% benefit to allowance rate for applications examined by RONEY, CELESTE A. This interview benefit is in the 70% percentile among all examiners. Recommendation: Interviews provide an above-average benefit with this examiner and are worth considering.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 19.1% of applications are subsequently allowed. This success rate is in the 19% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 30.8% of cases where such amendments are filed. This entry rate is in the 45% percentile among all examiners. Strategic Recommendation: This examiner shows below-average receptiveness to after-final amendments. You may need to file an RCE or appeal rather than relying on after-final amendment entry.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 45.5% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 41% percentile among all examiners. Note: Pre-appeal conferences show below-average success with this examiner. Consider whether your arguments are strong enough to warrant a PAC request.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 67.2% of appeals filed. This is in the 53% percentile among all examiners. Of these withdrawals, 62.2% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows above-average willingness to reconsider rejections during appeals. The mandatory appeal conference (MPEP § 1207.01) provides an opportunity for reconsideration.

Petition Practice

When applicants file petitions regarding this examiner's actions, 59.1% are granted (fully or in part). This grant rate is in the 63% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 1.7% of allowed cases (in the 72% percentile). This examiner makes examiner's amendments more often than average to place applications in condition for allowance (MPEP § 1302.04).

Quayle Actions: This examiner issues Ex Parte Quayle actions in 1.0% of allowed cases (in the 61% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Prepare for rigorous examination: With a below-average allowance rate, ensure your application has strong written description and enablement support. Consider filing a continuation if you need to add new matter.
  • Expect multiple rounds of prosecution: This examiner issues more office actions than average. Address potential issues proactively in your initial response and consider requesting an interview early in prosecution.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.